Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial
暂无分享,去创建一个
M. Cairo | C. Moorthy | S. Voss | Q. Shi | J. Hochberg | L. Harrison | C. Van de Ven | H. Islam | J. Basso | L. Klejmont | A. Flower | K. Bortfeld | P. Gerard | C. van de Ven